Table 3 Key results from the base-case analysis (Discounted, undiscounted)
From: Cost-consequence analysis of continuous denosumab therapy for osteoporosis treatment in South Korea
Variables | Discounted | Undiscounted | ||||
|---|---|---|---|---|---|---|
Dmab-C | Dmab-D | Difference | Dmab-C | Dmab-D | Difference | |
Total fracturea | 54.01 | 100.65 | -46.64 | 98.55 | 179.88 | -81.33 |
 Vertebral fracture | 13.89 | 48.09 | -34.21 | 25.01 | 84.49 | -59.48 |
 Non-vertebral fracture | 40.13 | 52.56 | -12.43 | 73.54 | 95.38 | -21.85 |
Fracture-related deatha | 1.76 | 3.06 | -1.29 | 5.77 | 9.82 | -4.04 |
Total lifetime costsb | 4,017,571 | 5,372,225 | -1,354,655 | 6,432,703 | 8,796,976 | -2,364,273 |
 Continuous drug costb | 717,120 | 0 | 717,120 | 754,004 | 0 | 754,004 |
 Subsequent drug costb | 1,846,137 | 2,654,788 | -808,651 | 3,025,230 | 3,940,990 | -915,760 |
 Fracture treatment costb | 1,454,314 | 2,717,437 | -1,263,124 | 2,653,470 | 4,855,986 | -2,202,517 |